Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
To compare recurrence free survival between two treatment groups (5 years with exemestane vs
2.5 to 3 years tamoxifen followed by 2 to 2.5 years of exemestane for a total duration of 5
years)
This Pfizer sponsored trial is part of an international collaboration of investigators
conducting 7 similar yet independent studies in 9 countries. This study is designed to be
part of the larger TEAM trial where the data from these 7 studies will be combined. A
pre-specified analysis of the pooled data will be conducted. Link to TEAM Trial
[971-ONC-0028-081/A5991026] Study Results:
http://clinicaltrials.gov/ct2/show/results/NCT00036270?term=971-ONC-0028-081&rank=1